Lys-SMCC-DM1 is primarily utilized in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. This compound serves as a linker-payload, connecting cytotoxic agents to monoclonal antibodies. The antibody specifically binds to antigens on cancer cells, delivering the cytotoxic payload directly to the tumor while minimizing damage to healthy tissues. Lys-SMCC-DM1 is particularly valued for its stability in circulation and efficient release of the cytotoxic agent once inside the target cells. Its application is crucial in enhancing the precision and efficacy of cancer treatments, reducing systemic toxicity, and improving patient outcomes.